TCF4 and gastric cancer: β-Catenin responsive transcription inhibitor 3/5 (iCRT3/5), which mainly blocks β-catenin-TCF4 interactions, is in the preclinical stage of gastric cancer treatment, and it can kill gastric cancer malignant cells and inhibit gastric cancer development (88).